Nymox Pharmaceutical Corporation NYMX
$ 0.2
-19.68%
Annual report 2022
added 12-21-2024
Country |
Canada |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
CEO |
Dr. Paul Averback |
Employees in the company |
3 |
Shares |
- |
Market Cap[1] |
$ 18.4 M |
EBITDA (LTM) |
$ -13.8 M |
P/E (LTM) |
-2.24 |
P/S (LTM) |
360.45 |
EPS (LTM) |
-0.17 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.